In a phase 1 trial by Martin and colleagues, observations at week 6 comparing tirzepatide vs once-daily liraglutide and placebo have shown that the use of the latter, provides a reduction on the desire for high-fat and high-sugar food by lowering activation in the cingulate gyri, hippocampus and orbitofrontal cortex assessed by MRI and blood-oxygen-level at these areas, meaning less appetite, early satiety, and less food craving with more reduction on weight loss at short term (181)
The GLP-1 market represents a major therapeutic class by revenue in the United States pharmaceutical landscape, with continued expansion expected
This could potentially result in less effective treatment
By leveraging plasma, the PlasmAGE tool uses a small electric discharge to treat the affected area without touching the skin, making it non-ablative and relatively pain-free
In clinical trials of GLP-1 medications, fat loss far outweighs losses of lean mass
The blend is convenient for studies where the fixed combination is appropriate or where exploring the combination effect is the primary interest
